Significant factors associated with MetS over time in SLICC Inception Cohort in age, race/ethnicity, gender and time adjusted univariate analyses*
| Variable | Adjusted OR | 95% CI |
|---|---|---|
| Age (years) | 1.08 | 1.06 to 1.11 |
| Previous MetS status | 18.6 | 13.7 to 25.4 |
| African ancestry race/ethnicity | 8.11 | 2.69 to 24.4 |
| Hispanic race/ethnicity | 5.17 | 2.28 to 11.7 |
| SLEDAI-2K>10 | 2.26 | 1.54 to 3.32 |
| SLEDAI-2K (per unit) | 1.11 | 1.07 to 1.16 |
| SLICC/ACR-DI>1 | 7.84 | 4.32 to 14.2 |
| Active renal disease† | 7.31 | 4.47 to 11.9 |
| Current oral CS | 3.94 | 2.38 to 6.55 |
| Average oral CS dose (mg)‡ | 1.06 | 1.05 to 1.08 |
| Highest oral CS dose (mg)‡ | 1.04 | 1.03 to 1.05 |
| Cumulative oral CS dose (g) | 1.11 | 1.07 to 1.16 |
| Current immunosuppressant | 2.06 | 1.42 to 3.00 |
| Current antimalarial | 0.21 | 0.14 to 0.34 |
*All variables are assessed as present or absent unless otherwise stated.
†Defined as haematuria >5 red blood cells/high power field; pyuria >5 white blood cells/high power field; new or recent increase of >500 mg 24 h protein; casts including granular or red blood cells; or consistent renal biopsy; nephrotic syndrome (proteinuria >3 g/24 h, oedema and increased BP). Other causes excluded.
‡Within preceding 12 months.
CS, corticosteroid; MetS, metabolic syndrome; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC/ACR-DI, Systemic Lupus Erythematosus International Collaborating Clinics/American College of Rheumatology Damage Index.